Literature DB >> 12907668

HMGA1 co-activates transcription in B cells through indirect association with DNA.

Kevin M McCarthy1, Daniel McDevit, Amy Andreucci, Raymond Reeves, Barbara S Nikolajczyk.   

Abstract

The immunoglobulin heavy chain enhancer, or mu enhancer, is required for B cell development. Only the appropriate combination of transcription factors results in B cell-specific enhancer activation. HMGA1 (formerly (HMG-I(Y)) is a proposed co-activator of the ETS transcription factors required for mu enhancer activity. HMGA1 associates with the ETS factor PU.1, resulting in changes in PU.1 structure, and enhanced transcriptional synergy with Ets-1 on the mu enhancer in nonlymphoid cells. New data show HMGA1 directly interacts with Ets-1 in addition to PU.1. In vitro HMGA1/Ets-1 interaction facilitates Ets-1/mu enhancer binding in the absence of an HMGA1.Ets-1.DNA complex. To address whether HMGA1 is present in the transcriptionally active mu nucleoprotein complex, we completed DNA pull-down assays to detect protein tethering in the context of protein/DNA interaction. Results show that HMGA1 is not tightly associated with mu enhancer DNA through PU.1 or Ets-1, despite strong associations between these proteins in solution. However, chromatin immunoprecipitation assays show HMGA1 associates with the endogenous enhancer in B cells. Furthermore, antisense HMGA1 substantially decreases mu enhancer activity in B cells. Taken together, these data suggest that HMGA1 functions as a transcriptional mu enhancer co-activator in B cells through indirect association with DNA.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12907668     DOI: 10.1074/jbc.M308586200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

Review 1.  The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development.

Authors:  T F Sumter; L Xian; T Huso; M Koo; Y-T Chang; T N Almasri; L Chia; C Inglis; D Reid; L M S Resar
Journal:  Curr Mol Med       Date:  2016       Impact factor: 2.222

Review 2.  Genome reading by the NF-κB transcription factors.

Authors:  Maria Carmen Mulero; Vivien Ya-Fan Wang; Tom Huxford; Gourisankar Ghosh
Journal:  Nucleic Acids Res       Date:  2019-11-04       Impact factor: 16.971

3.  Dynamic protein associations define two phases of IL-1beta transcriptional activation.

Authors:  Yue Zhang; Simona Saccani; Hyunjin Shin; Barbara S Nikolajczyk
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

4.  BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses.

Authors:  Anna C Belkina; Barbara S Nikolajczyk; Gerald V Denis
Journal:  J Immunol       Date:  2013-02-18       Impact factor: 5.422

Review 5.  Lymphocyte development: integration of DNA damage response signaling.

Authors:  Jeffrey J Bednarski; Barry P Sleckman
Journal:  Adv Immunol       Date:  2012       Impact factor: 3.543

6.  Module network inference from a cancer gene expression data set identifies microRNA regulated modules.

Authors:  Eric Bonnet; Marianthi Tatari; Anagha Joshi; Tom Michoel; Kathleen Marchal; Geert Berx; Yves Van de Peer
Journal:  PLoS One       Date:  2010-04-14       Impact factor: 3.240

7.  Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway.

Authors:  Shangqin Guo; Gail E Sonenshein
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

8.  Bright/ARID3A contributes to chromatin accessibility of the immunoglobulin heavy chain enhancer.

Authors:  Danjuan Lin; Gregory C Ippolito; Rui-Ting Zong; James Bryant; Janet Koslovsky; Philip Tucker
Journal:  Mol Cancer       Date:  2007-03-26       Impact factor: 27.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.